Michael E. Kelly MD, PhD Online Profile
Associate Professor
Medical College of Wisconsin
Department: Pediatrics
Division: Hematology/Oncology
Program: Oncology
Research Experience
LeukemiaVascular NeoplasmsClinical Expertise
HemangiomaLeukemiaNeoplasms, Vascular TissuePublications
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. (Chiu YE, Drolet BA, Blei F, Carcao M, Fangusaro J, Kelly ME, Krol A, Lofgren S, Mancini AJ, Metry DW, Recht M, Silverman RA, Tom WL, Pope E) Pediatr Blood Cancer 2012 Nov;59(5):934-8 PMID 22648868 Endoscopic management of gastrointestinal bleeding from multifocal lymphangioendotheliomatosis with thrombocytopenia: limited efficacy and complications. (Noel RJ, Duffy KJ, Kelly ME, Tondravi N, North PE, Drolet BA) J Pediatr Gastroenterol Nutr 2012 Jun;54(6):822-4 PMID 21788915 Microcystic adnexal carcinoma: the first reported congenital case. (Smart DR, Taintor AR, Kelly ME, Lyon VB, Segura A, Jensen JN, Drolet BA) Pediatr Dermatol 2011 Jan-Feb;28(1):35-8 PMID 21276051 Kasabach-Merritt phenomenon. (Kelly M) Pediatr Clin North Am 2010 Oct;57(5):1085-9 PMID 20888459 Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. (Kelly ME, Juern AM, Grossman WJ, Schauer DW, Drolet BA) Arch Dermatol 2010 Jul;146(7):767-74 PMID 20479291 Expanding the phenotype of multifocal lymphangioendotheliomatosis with thrombocytopenia. (Maronn M, Catrine K, North P, Browning MB, Kerschner JE, Noel R, Drolet BA, Kelly M) Pediatr Blood Cancer 2009 Apr;52(4):531-4 PMID 19058203 Renal cell carcinoma in a patient with cystinosis and inflammatory bowel disease: a case report. (Cameron C, Greenbaum L, Sato T, Trost B, Lundeen B, Kelly ME) Pediatr Nephrol 2008 Jul;23(7):1167-70 PMID 18286306 Measuring fatigue for children with cancer: development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F). (Lai JS, Cella D, Kupst MJ, Holm S, Kelly ME, Bode RK, Goldman S) J Pediatr Hematol Oncol 2007 Jul;29(7):471-9 PMID 17609625 Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. (Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S) Pediatr Blood Cancer 2008 Apr;50(4):822-5 PMID 17570702 Successful umbilical cord blood stem cell transplantation in a patient with Rothmund-Thomson syndrome and combined immunodeficiency. (Broom MA, Wang LL, Otta SK, Knutsen AP, Siegfried E, Batanian JR, Kelly ME, Shah M) Clin Genet 2006 Apr;69(4):337-43 PMID 16630167 Critical function of the CD40 pathway in parvovirus B19 infection revealed by a hypomorphic CD40 ligand mutation. (Blaeser F, Kelly M, Siegrist K, Storch GA, Buller RS, Whitlock J, Truong N, Chatila TA) Clin Immunol 2005 Dec;117(3):231-7 PMID 16169277 Posttransplantation lymphoproliferative disorder in children: clinical, histopathologic, and imaging features. (Pickhardt PJ, Siegel MJ, Hayashi RJ, Kelly M) Radiology 2000 Oct;217(1):16-25 PMID 11012419 High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. (Cohen AH, Sweet SC, Mendeloff E, Mallory GB Jr, Huddleston CB, Kraus M, Kelly M, Hayashi R, DeBaun MR) Am J Respir Crit Care Med 2000 Apr;161(4 Pt 1):1252-5 PMID 10764320 Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary. (Mistry MJ, Clay MA, Kelly ME, Steiner MA, Harmony JA) Cell Immunol 1995 Jan;160(1):14-23 PMID 7842480 Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. (Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM, Harmony JA) Cell Immunol 1994 Dec;159(2):124-39 PMID 7994749 alpha-Difluoromethylornithine induces differentiation of a human embryonal carcinoma cell line in vitro. (Uhl L, Kelly M, Schindler J) Biochem Biophys Res Commun 1986 Oct 15;140(1):66-73 PMID 3096321 Alterations in polyamine metabolism during embryonal carcinoma cell differentiation in vitro. (Kelly M, McCann PP, Schindler J) Dev Biol 1985 Oct;111(2):510-4 PMID 3930315 The response of several murine embryonal carcinoma cell lines to stimulation of differentiation by alpha-difluoromethylornithine. (Schindler J, Kelly M, McCann PP) J Cell Physiol 1985 Jan;122(1):1-6 PMID 3917438 Inhibition of ornithine decarboxylase induces embryonal carcinoma cell differentiation. (Schindler J, Kelly M, McCann PP) Biochem Biophys Res Commun 1983 Jul 18;114(1):410-7 PMID 6411082 Grants and Awards
Children's Oncology Group Chair's Grant - Budget Based (#9207366 03/01/2012 - 02/28/2013) Sponsor: Children's Hospital of PhiladelphiaChildren's Oncology Group - Patient Reimbursement (#9207365 03/01/2012 - 02/28/2013) Sponsor: Children's Hospital of PhiladelphiaEvent: The Children's Oncology Group (COG) Phase I/Pilot Consortium (#9207315 08/01/2011 - 07/31/2012) Sponsor: National Childhood Cancer FoundationCost: The Children's Oncology Group (COG) Phase I/Pilot Consortium (#9207633 08/01/2012 - 05/31/2013) Sponsor: National Childhood Cancer FoundationA Phase II Study of Sunitinib in Recurrent or Progressive Brain Tumors in Pediatric and Young Adult Patients; ACNS1021 PFIZER NO. WS281593-48 (#9305961 12/14/2012 - 12/13/2015) Sponsor: Children's Hospital of PhiladelphiaAn Open-Label Treatment Protocol For The Use Of Voraxaze As Adjunctive Treatment For Patients Experiencing Or At Risk Of Methotrexate Toxicity (PR001-CLN-pro016) (#9305859 12/02/2011 - 01/01/2013) Sponsor: CTI Clinical Trial Services, Inc.An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients with Relapsed or Refractory Acute Leukemia (#9305145 06/15/2010 - 06/14/2015) Sponsor: Cephalon, Inc.COG - A Phase II Pilot Trial of Bortezomib (PS-341, VELCADE IND 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed ALL and LL - Millennium (#9305962 12/14/2012 - 12/13/2015) Sponsor: Children's Hospital of PhiladelphiaCOG Non-Industry Work Order - St Baldricks (#9305979 03/01/2011 - 04/25/2012) Sponsor: Children's Hospital of Philadelphia100EUSA12 - An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of IV Erwinaze Following Allergy to Asparaginase, Pegaspargase or Calaspargase pegol in Children with ALL or Lymphoblastic Lymphoma (#9305917 10/16/2012 - 10/15/2015) Sponsor: EUSA PharmaCA180-372 (COG-AALL1122) , A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (#9305720 05/02/2012 - 03/05/2014) Sponsor: Children's Hospital of PhiladelphiaChildren's Oncology Group Chair's Grant - Budget Based (#9207957 03/01/2013 - 05/31/2013) Sponsor: Children's Hospital of PhiladelphiaChildren's Oncology Group - Patient Reimbursement (#9207970 03/01/2013 - 05/31/2013) Sponsor: Children's Hospital of PhiladelphiaChildren's Oncology Group (#9301162 11/14/1997 - 06/30/2017) Sponsor: VariousA Phase III Randomized Trial for Patients with de novo AML using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD (#9305931 12/14/2012 - 12/13/2013) Sponsor: Children's Hospital of PhiladelphiaEMTP: Treatment for Acute Lymphoblastic Leukemia using Erwinase Erwinia Chrysanthemi L-Asparaginase for Injection (#9305170 06/01/2010 - 09/04/2013) Sponsor: EUSA PharmaChildren's Oncology Group - Patient Reimbursement (#9206789 03/01/2011 - 02/29/2012) Sponsor: National Childhood Cancer Foundation
